AS/Spondyloarthritis

The definition of early axSpA based on expert consensus after going through the Delphi process by ASAS is that the duration of axial symptoms is equal or less than 2 years. Navarro-Compan V, Abst#OP0055 #EULAR2023 @RheumNow https://t.co/5byn0kBEIQ
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 04, 2023
Dual IL-17A/F inhibition with Bimekizumab reduced MRI inflammatory change in the SIJ and spine in AxSpA, and increasing proportion achieving MRI remission at Wk52, Abst#POS0246 #EULAR2023 @RheumNow https://t.co/w4VkkUklGl
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 03, 2023
The International Map of AxSpA (IMAS) of >5k patients: delay mean 7.4+/-9 years, 75% active disease, 60% poor mental health, 21% sick leave, 4.6 GP visits before diagnosis, fear=disease progression, hope=relief of pain, IMAS Abst#POS0298 #EULAR2023 @RheumNow https://t.co/wB9Jtbgvy7
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 03, 2023
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 03, 2023
In an early SpA (DESIR) cohort, the occurrence of a first pregnancy did not seem to increase the number of imaging abnormalities of the SIJ. Overall no significant changes in radiographic and MRI imaging abnormalities of the SIJ, Molto A, Abst#POS0303, #EULAR2023 @RheumNow

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 03, 2023
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 03, 2023
#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs. OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 03, 2023
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush @RheumNow( View Tweet )
Jun 02, 2023
We need to assess CV risk in IA but how? Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO Bummer: these 3 prediction tools are less accurate in IA but also OA. We need a dedicated tool. @Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 02, 2023
Just a reminder: nr-axSpA isn’t destined to become r-axSpA/AS. Life is more complicated than that. Between the natural history and TNFi, very small conversion rate post-10y. Of course, whatever the x-rays, it can still disable though DESIR cohort POS0675 #EULAR2023 @RheumNow https://t.co/29HeJXpK2S
David Liew @drdavidliew( View Tweet )
Jun 01, 2023
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
May 31, 2023
Chinese study 43 axSpA pts Rx w/ Secukinumab-37 pts had HBV & 16% (6) reactivated HBV after mean 9 mos of SEC (5 w/ chronic HBV, 1 occult HBV). 2 pts chronic HBV reactivated despite anti-HBV prophylaxis. 6 axSpA w/ LTBI - none had TB on SEC https://t.co/o4gA9mcD2R https://t.co/XKwp2z9U3K

Links:

Dr. John Cush @RheumNow( View Tweet )
May 31, 2023
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq

Links:

David Liew @drdavidliew( View Tweet )
May 31, 2023
AxSpA can be unequivocally diagnosed in the first 2 years of onset of chronic back pain with 30% definite with HLA-B27+ and imaging being the key SpA features from the SPACE cohort by Mary Lucy Marques, Abst #OP0005 @RheumNow https://t.co/m5umD00hDf
Dr. Antoni Chan @synovialjoints( View Tweet )
May 31, 2023
With all the benefits of MRI and expert rheumatologists, do our diagnoses of axSpA stick, two years later? Overwhelmingly yes, but sometimes we do actually have to change our minds. Beware the set and forget for our clinical diagnoses SPACE cohort #EULAR2023 OP0005 @RheumNow https://t.co/AN6XzqKlv3
David Liew @drdavidliew( View Tweet )
May 31, 2023
There are lots of reasons why axSpA treatments fail for patients. And as rheumatologists, we can’t just prescribe and walk away - we need to address each in turn, for our patients’ sake #EULAR2023 @RheumNow https://t.co/hzo57BaEXw
David Liew @drdavidliew( View Tweet )
May 31, 2023
Convention1.jpg

EULAR 2023: Featured Industry Presentations

Jack Cush, MD
May 30, 2023

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR 2023

Read Article
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2

Links:

Dr. John Cush @RheumNow( View Tweet )
May 30, 2023
UK Biobank cohort study (n=361,952) assessed BMI effects on rheumatic Dz risk. Higher BMI incr odds of RA (IRR=1.52), OA (IRR=1.49), PsA (IRR=1.80), gout (1.73), SpA(1.34); more pronounced in women for both gout and psoriatic arthropathy https://t.co/eLeeShSSv1 https://t.co/IjWF2EPqOR

Links:

Dr. John Cush @RheumNow( View Tweet )
May 29, 2023
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF

Links:

Dr. John Cush @RheumNow( View Tweet )
May 29, 2023
MRI study of SI jts in axSpA 196 pts shows w/ increasing bone marrow edema of SI, SI damage is likely. BME each quadrant incr odds: sclerosis (OR:1.9), erosions (1.9). BME lead to 5 yr SIJ damage if fluctuating (OR:5.6) or persistent (OR:7.5) https://t.co/Dkbcij5Uhv https://t.co/x83kErVb1E

Links:

Dr. John Cush @RheumNow( View Tweet )
May 29, 2023
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush @RheumNow( View Tweet )
May 29, 2023
⚠️Beware not all bone marrow oedema =#AxSpA on MRI ! Signal seen in 17% volunteers at SIJs @DrPoddubnyy #RNL2023 https://t.co/xTKuSRXK72 https://t.co/c09QjSkJBP

Links:

Dr. John Cush @RheumNow( View Tweet )
May 29, 2023
Dennis Poddubnyy #RNL2023 MRI sequences for axSpA: Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression Semi-axial- T2 STIR @RheumNow https://t.co/aidLu7GcQH https://t.co/YOrboYl6pW

Links:

Dr. John Cush @RheumNow( View Tweet )
May 28, 2023
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS. *Erosions in 3 or more SIJ quadrants *BME in 4 or more SIJ quadrants *Fat lesions in 5 of more SIJ quadrants #RNL2023 @RheumNow https://t.co/T9iWLcNL8b https://t.co/BskCNz9Klj

Links:

Dr. John Cush @RheumNow( View Tweet )
May 27, 2023

Recent Blogs

A Domain-Based Approach to the GRAPPA Psoriatic Arthritis Treatment Recommendations

Laura Coates
Jul 05, 2022
heel enthesitis spur calcaneal

With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.

Read Post

    Do you get our email newsletter?

    Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

    Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

    Copyright 2023 All Rights Reserved.

    ×